TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01431625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Training (endurance and strength exercises)
Description: All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~2. - Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Training (endurance and strength exercises)
Description: All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~2. - Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient.
Study: NCT04460118

Intervention type: PROCEDURE
Intervention: Bristow surgery fixed by the screw
Description: Bristow surgery fixed by the screw

Intervention type: PROCEDURE
Intervention: Bristow surgery fixed by the suture button
Description: Bristow surgery fixed by the suture button
Study: NCT04004611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV and SC
Study: NCT01296451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: genetic vaccine against Hepatitis virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: genetic vaccine against Hepatitis virus infection
Study: NCT03594669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
Study: NCT02248792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT02821273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified INSURE technique
Description: modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: INSURE technique
Description: INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
Study: NCT01785966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily checklist and clinician prompting
Description: Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items.
Study: NCT01992380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
Study: NCT01413568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Transplant
Study: NCT01983748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells loaded with autologous Tumor RNA
Study: NCT03671005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Description: see above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: see above
Study: NCT05418036

Intervention type: DRUG
Group type: OTHER
Intervention: Sotalol Oral Tablet
Description: Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
Study: NCT03118583

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg/day of dietary supplement containing carrageenan
Description: 300 mg/day of dietary supplement containing carrageenan.
Study: NCT01420055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Study: NCT02605486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study: NCT04960111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSA
Description: application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
Study: NCT03907124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genetically-guided treatment with FDA-approved psychotropic drugs
Description: Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
Study: NCT04041960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
Study: NCT00598429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Prostaglandin E1
Description: Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Prostaglandin E1
Description: Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Prostaglandin E1
Description: Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
Study: NCT04294966

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: Administering dextrose to healthy volunteers for our placebo group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
Study: NCT04292626

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT with 99mTc-1-thio-D-glucose
Description: One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Study: NCT04432987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days
Study: NCT04678492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
Study: NCT00965224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccination (active specific immunotherapy)
Study: NCT00925613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Proseal
Description: Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal tube
Description: Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
Study: NCT00408213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study: NCT03433001

Intervention type: DRUG
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study: NCT01280370

Intervention type: PROCEDURE
Intervention: Abdominal surgery
Description: intraoperative mesh implantation
Study: NCT00130533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT03365024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy for Insomnia
Description: A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: A web-based program will deliver components of sleep education via an Internet platform
Study: NCT02509871

Intervention type: OTHER
Group type: OTHER
Intervention: Body composition measurement
Description: DXA, impedance
Study: NCT01186978

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: 1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
Study: NCT01685970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High volume split-dose PEG
Description: High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 sachets of picosulfate
Description: 2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
Study: NCT04193800

Intervention type: OTHER
Intervention: 10-week rotation in primary care setting
Description: Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
Study: NCT03901326

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-FFR assessment
Description: When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DEEPVESSEL FFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values based on a machine learning algorithm. The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DEEPVESSEL FFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value at distance of 20mm away from the lesion of interest.
Study: NCT03058211

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Standard protocols

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Standard protocols

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic resonance
Description: MRI with late gadolinium increase and T1 mapping

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic resonance
Description: MRI with late gadolinium increase and T1 mapping
Study: NCT03939377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and treatment
Description: EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire and treatment
Description: EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
Study: NCT00006213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-214662
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies